Effects of diazoxide administration on plasma glucose, insulin, and lipids in Von Gierke's disease.
D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D003981:Diazoxide / Q000009:adverse effects; D003875:Drug Eruptions; D004342:Drug Hypersensitivity; D005951:Glucose Tolerance Test; D005989:Glycerides / Q000378:metabolism*; D006003:Glycogen; D005953:Glycogen Storage Disease Type I / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D006949:Hyperlipidemias / Q000188:drug therapy; D007003:Hypoglycemia / Q000188:drug therapy; D007328:Insulin; D008055:Lipids; D008297:Male; D014280:Triglycerides / Q000378:metabolism; D014973:Xanthomatosis / Q000209:etiology
D000959:Antihypertensive Agents; D005989:Glycerides; D007328:Insulin; D008055:Lipids; D014280:Triglycerides; D006003:Glycogen; D003981:Diazoxide